622 related articles for article (PubMed ID: 32140943)
1. Dilemma and Challenge of Immunotherapy for Pancreatic Cancer.
Wu J; Cai J
Dig Dis Sci; 2021 Feb; 66(2):359-368. PubMed ID: 32140943
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for pancreatic cancer: A long and hopeful journey.
Xu JW; Wang L; Cheng YG; Zhang GY; Hu SY; Zhou B; Zhan HX
Cancer Lett; 2018 Jul; 425():143-151. PubMed ID: 29605510
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in pancreatic cancer: New hope or mission impossible?
Jiang J; Zhou H; Ni C; Hu X; Mou Y; Huang D; Yang L
Cancer Lett; 2019 Mar; 445():57-64. PubMed ID: 30641107
[TBL] [Abstract][Full Text] [Related]
4. Emerging trends in the immunotherapy of pancreatic cancer.
Banerjee K; Kumar S; Ross KA; Gautam S; Poelaert B; Nasser MW; Aithal A; Bhatia R; Wannemuehler MJ; Narasimhan B; Solheim JC; Batra SK; Jain M
Cancer Lett; 2018 Mar; 417():35-46. PubMed ID: 29242097
[TBL] [Abstract][Full Text] [Related]
5. Killing the "BAD": Challenges for immunotherapy in pancreatic cancer.
Li TJ; Wang WQ; Yu XJ; Liu L
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188384. PubMed ID: 32531324
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
Hosseinkhani N; Derakhshani A; Kooshkaki O; Abdoli Shadbad M; Hajiasgharzadeh K; Baghbanzadeh A; Safarpour H; Mokhtarzadeh A; Brunetti O; Yue SC; Silvestris N; Baradaran B
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167514
[TBL] [Abstract][Full Text] [Related]
7. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy.
Torphy RJ; Schulick RD; Zhu Y
Mol Carcinog; 2020 Jul; 59(7):775-782. PubMed ID: 32166821
[TBL] [Abstract][Full Text] [Related]
8. A novel target for combination immunotherapy in pancreatic cancer: IL-1β mediates immunosuppression in the tumour microenvironment.
Winograd R; Simeone DM; Bar-Sagi D
Br J Cancer; 2021 May; 124(11):1754-1756. PubMed ID: 33758330
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment.
Looi CK; Chung FF; Leong CO; Wong SF; Rosli R; Mai CW
J Exp Clin Cancer Res; 2019 Apr; 38(1):162. PubMed ID: 30987642
[TBL] [Abstract][Full Text] [Related]
10. Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer.
Cifaldi L; Di Santo J; Olive D
Front Immunol; 2020; 11():1132. PubMed ID: 32612604
[No Abstract] [Full Text] [Related]
11. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
12. Turning tumors from cold to inflamed to improve immunotherapy response.
Gerard CL; Delyon J; Wicky A; Homicsko K; Cuendet MA; Michielin O
Cancer Treat Rev; 2021 Dec; 101():102227. PubMed ID: 34656019
[TBL] [Abstract][Full Text] [Related]
13. Frontiers in cancer immunotherapy-a symposium report.
Cable J; Greenbaum B; Pe'er D; Bollard CM; Bruni S; Griffin ME; Allison JP; Wu CJ; Subudhi SK; Mardis ER; Brentjens R; Sosman JA; Cemerski S; Zavitsanou AM; Proia T; Egeblad M; Nolan G; Goswami S; Spranger S; Mackall CL
Ann N Y Acad Sci; 2021 Apr; 1489(1):30-47. PubMed ID: 33184911
[TBL] [Abstract][Full Text] [Related]
14. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
Ibrahim AM; Wang YH
World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
[TBL] [Abstract][Full Text] [Related]
15. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
Oura K; Morishita A; Tani J; Masaki T
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
[TBL] [Abstract][Full Text] [Related]
16. Regulation and modulation of antitumor immunity in pancreatic cancer.
Leinwand J; Miller G
Nat Immunol; 2020 Oct; 21(10):1152-1159. PubMed ID: 32807942
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of pancreatic cancer.
Sunami Y; Kleeff J
Prog Mol Biol Transl Sci; 2019; 164():189-216. PubMed ID: 31383405
[TBL] [Abstract][Full Text] [Related]
18. Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects.
Chen X; Zhang W; Yang W; Zhou M; Liu F
Aging (Albany NY); 2022 Jan; 14(2):1048-1064. PubMed ID: 35037899
[TBL] [Abstract][Full Text] [Related]
19. Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade.
Liu Y; Cai J; Liu W; Lin Y; Guo L; Liu X; Qin Z; Xu C; Zhang Y; Su X; Deng K; Yan G; Liang J
Cell Death Dis; 2020 Dec; 11(12):1062. PubMed ID: 33311488
[TBL] [Abstract][Full Text] [Related]
20. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]